SRC and breast cancer: This confirms the significance of FOXD1-dependent RalA-ANXA2-Src-ERK1/2 signaling cascade in promoting CTC formation and highlights that ERK1/2 inhibitor SCH772984 can be a potential and effective strategy preventing CTC formation and metastasis in BC, particularly in early BC.